Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study
Use of colistin methanesulfonate (CMS) was abandoned in the 1970s because of excessive nephrotoxicity, but it has been reintroduced as a last-resort treatment for extensively drug-resistant infections caused by gram-negative bacteria (Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneum...
Gespeichert in:
Veröffentlicht in: | Critical care (London, England) England), 2013-08, Vol.17 (4), p.R174-R174, Article R174 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | R174 |
---|---|
container_issue | 4 |
container_start_page | R174 |
container_title | Critical care (London, England) |
container_volume | 17 |
creator | Rocco, Monica Montini, Luca Alessandri, Elisa Venditti, Mario Laderchi, Amalia De Pascale, Gennaro Raponi, Giammarco Vitale, Michela Pietropaoli, Paolo Antonelli, Massimo |
description | Use of colistin methanesulfonate (CMS) was abandoned in the 1970s because of excessive nephrotoxicity, but it has been reintroduced as a last-resort treatment for extensively drug-resistant infections caused by gram-negative bacteria (Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumonia). We conducted a retrospective cohort study to evaluate risk factors for new-onset acute kidney injury (AKI) in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics.
The cohort consisted of 279 adults admitted to two general ICUs in teaching hospitals between 1 April 2009 and 30 June 2011 with 1) no evidence on admission of acute or chronic kidney disease; and 2) treatment for more than seven days with CMS and/or other nephrotoxic antimicrobials (NAs, that is, aminoglycosides, glycopeptides). Logistic regression analysis was used to identify risk factors associated with this outcome.
The 279 cases that met the inclusion criteria included 147 patients treated with CMS, alone (n = 90) or with NAs (n = 57), and 132 treated with NAs alone. The 111 (40%) who developed AKI were significantly older and had significantly higher Simplified Acute Physiology Score II (SAPS II) scores than those who did not develop AKI, but rates of hypertension, diabetes mellitus and congestive heart failure were similar in the two groups. The final logistic regression model showed that in the 147 patients who received CMS alone or with NAs, onset of AKI during the ICU stay was associated with septic shock and with SAPS II scores ≥43. Similar results were obtained in the 222 patients treated with CMS alone or NAs alone.
In severely ill ICU patients without pre-existing renal disease who receive CMS high-dose for more than seven days, CMS therapy does not appear to be a risk factor for this outcome. Instead, the development of AKI was strongly correlated with the presence of septic shock and with the severity of the patients as reflected by the SAPS II score. |
doi_str_mv | 10.1186/cc12853 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4056524</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A534778253</galeid><sourcerecordid>A534778253</sourcerecordid><originalsourceid>FETCH-LOGICAL-c436t-d2ec76e5bdbe23440541537d12ebd04f77415586253502dbe066c503e36e5bb13</originalsourceid><addsrcrecordid>eNptUl1r3TAMDWNj7bqxfzAMe9hT2jj-SO4eBqXsCwqDscHegmMrN2oTO9jOpfff7adNl9uVFYYfZElH50hCRfGaV-ect_rCWl63SjwpTrnUutTV5tdT-gstSwqrk-JFSjdVxZtWi-fFSS02UvFNc1r8_o7plg3G5hATG0Jkxq4Z2C06D3uG_maNB8NsxIzWTBN508QWkxF8TiyCBdyh37IRtyMhczQ78GFNzIUEiYWB2TBhykQyQx6Nh7ROQ_CGZIx3F6QZ8giReVjGGHK4Q0uJjD0GkkzvmSGVHENawGbcAfGNIWaW8ur2L4tng5kSvLq3Z8XPTx9_XH0pr799_np1eV1aKXQuXQ220aB610MtpKyU5Eo0jtfQu0oOTUO-anVN26pqAlVaW1UJEIeinouz4sORd1n7GZyFw6BTt0ScTdx3wWD3OONx7LZh15GUVrUkgrdHgq2ZoEM_BILZGZPtLpWQTdOSNqHO_4Oi52BGGzwMSPFHBe-OBZYWlCIMDy3xqjvcRnd_G4R88-8ED7i_xyD-ABaDumE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>SpringerLink Journals - AutoHoldings</source><source>Springer Nature OA Free Journals</source><creator>Rocco, Monica ; Montini, Luca ; Alessandri, Elisa ; Venditti, Mario ; Laderchi, Amalia ; De Pascale, Gennaro ; Raponi, Giammarco ; Vitale, Michela ; Pietropaoli, Paolo ; Antonelli, Massimo</creator><creatorcontrib>Rocco, Monica ; Montini, Luca ; Alessandri, Elisa ; Venditti, Mario ; Laderchi, Amalia ; De Pascale, Gennaro ; Raponi, Giammarco ; Vitale, Michela ; Pietropaoli, Paolo ; Antonelli, Massimo</creatorcontrib><description>Use of colistin methanesulfonate (CMS) was abandoned in the 1970s because of excessive nephrotoxicity, but it has been reintroduced as a last-resort treatment for extensively drug-resistant infections caused by gram-negative bacteria (Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumonia). We conducted a retrospective cohort study to evaluate risk factors for new-onset acute kidney injury (AKI) in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics.
The cohort consisted of 279 adults admitted to two general ICUs in teaching hospitals between 1 April 2009 and 30 June 2011 with 1) no evidence on admission of acute or chronic kidney disease; and 2) treatment for more than seven days with CMS and/or other nephrotoxic antimicrobials (NAs, that is, aminoglycosides, glycopeptides). Logistic regression analysis was used to identify risk factors associated with this outcome.
The 279 cases that met the inclusion criteria included 147 patients treated with CMS, alone (n = 90) or with NAs (n = 57), and 132 treated with NAs alone. The 111 (40%) who developed AKI were significantly older and had significantly higher Simplified Acute Physiology Score II (SAPS II) scores than those who did not develop AKI, but rates of hypertension, diabetes mellitus and congestive heart failure were similar in the two groups. The final logistic regression model showed that in the 147 patients who received CMS alone or with NAs, onset of AKI during the ICU stay was associated with septic shock and with SAPS II scores ≥43. Similar results were obtained in the 222 patients treated with CMS alone or NAs alone.
In severely ill ICU patients without pre-existing renal disease who receive CMS high-dose for more than seven days, CMS therapy does not appear to be a risk factor for this outcome. Instead, the development of AKI was strongly correlated with the presence of septic shock and with the severity of the patients as reflected by the SAPS II score.</description><identifier>ISSN: 1364-8535</identifier><identifier>EISSN: 1466-609X</identifier><identifier>EISSN: 1364-8535</identifier><identifier>DOI: 10.1186/cc12853</identifier><identifier>PMID: 23945197</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Acute Kidney Injury - chemically induced ; Acute Kidney Injury - diagnosis ; Acute Kidney Injury - epidemiology ; Acute renal failure ; Adult ; Aged ; Aminoglycosides ; Anti-Bacterial Agents - administration & dosage ; Anti-Bacterial Agents - adverse effects ; Chronic kidney failure ; Cohort Studies ; Colistin ; Colistin - administration & dosage ; Colistin - adverse effects ; Critical Illness - epidemiology ; Critical Illness - therapy ; Critically ill ; Diabetes ; Drug resistance in microorganisms ; Evidence (Law) ; Female ; Health aspects ; Hospital patients ; Humans ; Infusions, Intravenous ; Kidney - drug effects ; Kidney - pathology ; Male ; Medical research ; Medicine, Experimental ; Middle Aged ; Physiological aspects ; Prospective Studies ; Retrospective Studies ; Risk Factors ; Sepsis - drug therapy ; Sepsis - epidemiology ; Septic shock</subject><ispartof>Critical care (London, England), 2013-08, Vol.17 (4), p.R174-R174, Article R174</ispartof><rights>COPYRIGHT 2013 BioMed Central Ltd.</rights><rights>Copyright © 2013 Rocco et al.; licensee BioMed Central Ltd. 2013 Rocco et al.; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c436t-d2ec76e5bdbe23440541537d12ebd04f77415586253502dbe066c503e36e5bb13</citedby><cites>FETCH-LOGICAL-c436t-d2ec76e5bdbe23440541537d12ebd04f77415586253502dbe066c503e36e5bb13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4056524/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4056524/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23945197$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rocco, Monica</creatorcontrib><creatorcontrib>Montini, Luca</creatorcontrib><creatorcontrib>Alessandri, Elisa</creatorcontrib><creatorcontrib>Venditti, Mario</creatorcontrib><creatorcontrib>Laderchi, Amalia</creatorcontrib><creatorcontrib>De Pascale, Gennaro</creatorcontrib><creatorcontrib>Raponi, Giammarco</creatorcontrib><creatorcontrib>Vitale, Michela</creatorcontrib><creatorcontrib>Pietropaoli, Paolo</creatorcontrib><creatorcontrib>Antonelli, Massimo</creatorcontrib><title>Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study</title><title>Critical care (London, England)</title><addtitle>Crit Care</addtitle><description>Use of colistin methanesulfonate (CMS) was abandoned in the 1970s because of excessive nephrotoxicity, but it has been reintroduced as a last-resort treatment for extensively drug-resistant infections caused by gram-negative bacteria (Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumonia). We conducted a retrospective cohort study to evaluate risk factors for new-onset acute kidney injury (AKI) in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics.
The cohort consisted of 279 adults admitted to two general ICUs in teaching hospitals between 1 April 2009 and 30 June 2011 with 1) no evidence on admission of acute or chronic kidney disease; and 2) treatment for more than seven days with CMS and/or other nephrotoxic antimicrobials (NAs, that is, aminoglycosides, glycopeptides). Logistic regression analysis was used to identify risk factors associated with this outcome.
The 279 cases that met the inclusion criteria included 147 patients treated with CMS, alone (n = 90) or with NAs (n = 57), and 132 treated with NAs alone. The 111 (40%) who developed AKI were significantly older and had significantly higher Simplified Acute Physiology Score II (SAPS II) scores than those who did not develop AKI, but rates of hypertension, diabetes mellitus and congestive heart failure were similar in the two groups. The final logistic regression model showed that in the 147 patients who received CMS alone or with NAs, onset of AKI during the ICU stay was associated with septic shock and with SAPS II scores ≥43. Similar results were obtained in the 222 patients treated with CMS alone or NAs alone.
In severely ill ICU patients without pre-existing renal disease who receive CMS high-dose for more than seven days, CMS therapy does not appear to be a risk factor for this outcome. Instead, the development of AKI was strongly correlated with the presence of septic shock and with the severity of the patients as reflected by the SAPS II score.</description><subject>Acute Kidney Injury - chemically induced</subject><subject>Acute Kidney Injury - diagnosis</subject><subject>Acute Kidney Injury - epidemiology</subject><subject>Acute renal failure</subject><subject>Adult</subject><subject>Aged</subject><subject>Aminoglycosides</subject><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Anti-Bacterial Agents - adverse effects</subject><subject>Chronic kidney failure</subject><subject>Cohort Studies</subject><subject>Colistin</subject><subject>Colistin - administration & dosage</subject><subject>Colistin - adverse effects</subject><subject>Critical Illness - epidemiology</subject><subject>Critical Illness - therapy</subject><subject>Critically ill</subject><subject>Diabetes</subject><subject>Drug resistance in microorganisms</subject><subject>Evidence (Law)</subject><subject>Female</subject><subject>Health aspects</subject><subject>Hospital patients</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Kidney - drug effects</subject><subject>Kidney - pathology</subject><subject>Male</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Middle Aged</subject><subject>Physiological aspects</subject><subject>Prospective Studies</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Sepsis - drug therapy</subject><subject>Sepsis - epidemiology</subject><subject>Septic shock</subject><issn>1364-8535</issn><issn>1466-609X</issn><issn>1364-8535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptUl1r3TAMDWNj7bqxfzAMe9hT2jj-SO4eBqXsCwqDscHegmMrN2oTO9jOpfff7adNl9uVFYYfZElH50hCRfGaV-ect_rCWl63SjwpTrnUutTV5tdT-gstSwqrk-JFSjdVxZtWi-fFSS02UvFNc1r8_o7plg3G5hATG0Jkxq4Z2C06D3uG_maNB8NsxIzWTBN508QWkxF8TiyCBdyh37IRtyMhczQ78GFNzIUEiYWB2TBhykQyQx6Nh7ROQ_CGZIx3F6QZ8giReVjGGHK4Q0uJjD0GkkzvmSGVHENawGbcAfGNIWaW8ur2L4tng5kSvLq3Z8XPTx9_XH0pr799_np1eV1aKXQuXQ220aB610MtpKyU5Eo0jtfQu0oOTUO-anVN26pqAlVaW1UJEIeinouz4sORd1n7GZyFw6BTt0ScTdx3wWD3OONx7LZh15GUVrUkgrdHgq2ZoEM_BILZGZPtLpWQTdOSNqHO_4Oi52BGGzwMSPFHBe-OBZYWlCIMDy3xqjvcRnd_G4R88-8ED7i_xyD-ABaDumE</recordid><startdate>20130814</startdate><enddate>20130814</enddate><creator>Rocco, Monica</creator><creator>Montini, Luca</creator><creator>Alessandri, Elisa</creator><creator>Venditti, Mario</creator><creator>Laderchi, Amalia</creator><creator>De Pascale, Gennaro</creator><creator>Raponi, Giammarco</creator><creator>Vitale, Michela</creator><creator>Pietropaoli, Paolo</creator><creator>Antonelli, Massimo</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20130814</creationdate><title>Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study</title><author>Rocco, Monica ; Montini, Luca ; Alessandri, Elisa ; Venditti, Mario ; Laderchi, Amalia ; De Pascale, Gennaro ; Raponi, Giammarco ; Vitale, Michela ; Pietropaoli, Paolo ; Antonelli, Massimo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c436t-d2ec76e5bdbe23440541537d12ebd04f77415586253502dbe066c503e36e5bb13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Acute Kidney Injury - chemically induced</topic><topic>Acute Kidney Injury - diagnosis</topic><topic>Acute Kidney Injury - epidemiology</topic><topic>Acute renal failure</topic><topic>Adult</topic><topic>Aged</topic><topic>Aminoglycosides</topic><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Anti-Bacterial Agents - adverse effects</topic><topic>Chronic kidney failure</topic><topic>Cohort Studies</topic><topic>Colistin</topic><topic>Colistin - administration & dosage</topic><topic>Colistin - adverse effects</topic><topic>Critical Illness - epidemiology</topic><topic>Critical Illness - therapy</topic><topic>Critically ill</topic><topic>Diabetes</topic><topic>Drug resistance in microorganisms</topic><topic>Evidence (Law)</topic><topic>Female</topic><topic>Health aspects</topic><topic>Hospital patients</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Kidney - drug effects</topic><topic>Kidney - pathology</topic><topic>Male</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Middle Aged</topic><topic>Physiological aspects</topic><topic>Prospective Studies</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Sepsis - drug therapy</topic><topic>Sepsis - epidemiology</topic><topic>Septic shock</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rocco, Monica</creatorcontrib><creatorcontrib>Montini, Luca</creatorcontrib><creatorcontrib>Alessandri, Elisa</creatorcontrib><creatorcontrib>Venditti, Mario</creatorcontrib><creatorcontrib>Laderchi, Amalia</creatorcontrib><creatorcontrib>De Pascale, Gennaro</creatorcontrib><creatorcontrib>Raponi, Giammarco</creatorcontrib><creatorcontrib>Vitale, Michela</creatorcontrib><creatorcontrib>Pietropaoli, Paolo</creatorcontrib><creatorcontrib>Antonelli, Massimo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Critical care (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rocco, Monica</au><au>Montini, Luca</au><au>Alessandri, Elisa</au><au>Venditti, Mario</au><au>Laderchi, Amalia</au><au>De Pascale, Gennaro</au><au>Raponi, Giammarco</au><au>Vitale, Michela</au><au>Pietropaoli, Paolo</au><au>Antonelli, Massimo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study</atitle><jtitle>Critical care (London, England)</jtitle><addtitle>Crit Care</addtitle><date>2013-08-14</date><risdate>2013</risdate><volume>17</volume><issue>4</issue><spage>R174</spage><epage>R174</epage><pages>R174-R174</pages><artnum>R174</artnum><issn>1364-8535</issn><eissn>1466-609X</eissn><eissn>1364-8535</eissn><abstract>Use of colistin methanesulfonate (CMS) was abandoned in the 1970s because of excessive nephrotoxicity, but it has been reintroduced as a last-resort treatment for extensively drug-resistant infections caused by gram-negative bacteria (Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumonia). We conducted a retrospective cohort study to evaluate risk factors for new-onset acute kidney injury (AKI) in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics.
The cohort consisted of 279 adults admitted to two general ICUs in teaching hospitals between 1 April 2009 and 30 June 2011 with 1) no evidence on admission of acute or chronic kidney disease; and 2) treatment for more than seven days with CMS and/or other nephrotoxic antimicrobials (NAs, that is, aminoglycosides, glycopeptides). Logistic regression analysis was used to identify risk factors associated with this outcome.
The 279 cases that met the inclusion criteria included 147 patients treated with CMS, alone (n = 90) or with NAs (n = 57), and 132 treated with NAs alone. The 111 (40%) who developed AKI were significantly older and had significantly higher Simplified Acute Physiology Score II (SAPS II) scores than those who did not develop AKI, but rates of hypertension, diabetes mellitus and congestive heart failure were similar in the two groups. The final logistic regression model showed that in the 147 patients who received CMS alone or with NAs, onset of AKI during the ICU stay was associated with septic shock and with SAPS II scores ≥43. Similar results were obtained in the 222 patients treated with CMS alone or NAs alone.
In severely ill ICU patients without pre-existing renal disease who receive CMS high-dose for more than seven days, CMS therapy does not appear to be a risk factor for this outcome. Instead, the development of AKI was strongly correlated with the presence of septic shock and with the severity of the patients as reflected by the SAPS II score.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>23945197</pmid><doi>10.1186/cc12853</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1364-8535 |
ispartof | Critical care (London, England), 2013-08, Vol.17 (4), p.R174-R174, Article R174 |
issn | 1364-8535 1466-609X 1364-8535 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4056524 |
source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection; SpringerLink Journals - AutoHoldings; Springer Nature OA Free Journals |
subjects | Acute Kidney Injury - chemically induced Acute Kidney Injury - diagnosis Acute Kidney Injury - epidemiology Acute renal failure Adult Aged Aminoglycosides Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - adverse effects Chronic kidney failure Cohort Studies Colistin Colistin - administration & dosage Colistin - adverse effects Critical Illness - epidemiology Critical Illness - therapy Critically ill Diabetes Drug resistance in microorganisms Evidence (Law) Female Health aspects Hospital patients Humans Infusions, Intravenous Kidney - drug effects Kidney - pathology Male Medical research Medicine, Experimental Middle Aged Physiological aspects Prospective Studies Retrospective Studies Risk Factors Sepsis - drug therapy Sepsis - epidemiology Septic shock |
title | Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T20%3A08%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risk%20factors%20for%20acute%20kidney%20injury%20in%20critically%20ill%20patients%20receiving%20high%20intravenous%20doses%20of%20colistin%20methanesulfonate%20and/or%20other%20nephrotoxic%20antibiotics:%20a%20retrospective%20cohort%20study&rft.jtitle=Critical%20care%20(London,%20England)&rft.au=Rocco,%20Monica&rft.date=2013-08-14&rft.volume=17&rft.issue=4&rft.spage=R174&rft.epage=R174&rft.pages=R174-R174&rft.artnum=R174&rft.issn=1364-8535&rft.eissn=1466-609X&rft_id=info:doi/10.1186/cc12853&rft_dat=%3Cgale_pubme%3EA534778253%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/23945197&rft_galeid=A534778253&rfr_iscdi=true |